Paris, France and Camberley, UK – 28 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited revenues for the year ended 31 December 2019 and provides an operational update. The Company will report its full year results in April 2020. http://novacyt.com/wp-content/uploads/2020/01/Novacyt-full-year-trading-and-operational-update-ENGLISH.pdf
Visit PageNews and Events
Partenariat entre Primerdesign et le groupe VGS en France
L’accord commercial concerne des diagnostics moléculaires pour le marché croissant de l’aquaculture et de l’aquariophilie Paris, France et Camberley, UK – 17 janvier 2020 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce aujourd’hui que sa division de tests moléculaires Primerdesign Ltd (“Primerdesign”) a signé un accord commercial exclusif avec Atothis
Visit PagePrimerdesign partners with VGS Group in France
Commercial agreement includes molecular diagnostics for the growing aquaculture and aquamarine market Paris, France and Camberley, UK – 17 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its molecular testing division, Primerdesign Ltd (“Primerdesign”), has signed an exclusive commercial agreement with Atothis SARL, part of VGS Invest
Visit Page